康寧傑瑞製藥-B(09966.HK)：治療實體瘤藥物完成I期臨床研究首例患者給藥

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

康寧傑瑞製藥-B(09966.HK)：治療實體瘤藥物完成I期臨床研究首例患者給藥

阿思達克 09-20 09:35

康寧傑瑞製藥-B(09966.HK)公布，其自主研發的JSKN003抗體偶聯藥物在澳洲進行的I期臨床研究成功完成首例患者給藥。該臨床研究是一項開放性標籤、多中心、劑量遞增的I期臨床研究，以評估JSKN003在晚期實體瘤患者中的安全性、耐受性和初步有效性，並確定II期推薦劑量(RP2D)。

康寧傑瑞製藥-B(09966.HK)

Relevant Stocks

康寧傑瑞製藥-B(09966.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

康寧傑瑞製藥-B(09966.HK)：治療實體瘤藥物完成I期臨床研究首例患者給藥

Services

About Us

Agreement Statement